Display options
Cite
Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027doi: 10.1155/2014/357027.
Iqbal, N., & Iqbal, N. (2014). Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice, 2014357027. https://doi.org/10.1155/2014/357027
Iqbal, Nida, and Iqbal, Naveed. "Imatinib: a breakthrough of targeted therapy in cancer." Chemotherapy research and practice vol. 2014 (2014): 357027. doi: https://doi.org/10.1155/2014/357027
Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. doi: 10.1155/2014/357027. Epub 2014 May 19. PMID: 24963404; PMCID: PMC4055302.
Copy Download .nbib Format: NLM
Share it on

Chemother Res Pract. 2014;2014:357027. doi: 10.1155/2014/357027. Epub 2014 May 19.

Imatinib: a breakthrough of targeted therapy in cancer.

Chemotherapy research and practice

Nida Iqbal, Naveed Iqbal

Affiliations

  1. Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
  2. Department of Anaesthesia and Intensive Care Unit, Indraprastha Apollo Hospital, New Delhi 110076, India.

PMID: 24963404 PMCID: PMC4055302 DOI: 10.1155/2014/357027

Abstract

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of various cancers and represents a therapeutic breakthrough. Imatinib was one of the first cancer therapies to show the potential for such targeted action. Imatinib, an oral targeted therapy, inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRA. Apart from its remarkable success in CML and GIST, Imatinib benefits various other tumors caused by Imatinib-specific abnormalities of PDGFR and c-KIT. Imatinib has also been proven to be effective in steroid-refractory chronic graft-versus-host disease because of its anti-PDGFR action. This paper is a comprehensive review of the role of Imatinib in oncology.

References

  1. Eur J Cancer. 2003 Sep;39(14):2006-11 - PubMed
  2. Ann Oncol. 2012 Nov;23(11):2776-2781 - PubMed
  3. Clin Oncol (R Coll Radiol). 2009 Dec;21(10):775-80 - PubMed
  4. Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 - PubMed
  5. N Engl J Med. 2003 Mar 27;348(13):1201-14 - PubMed
  6. Dermatology. 2007;214(1):15-20 - PubMed
  7. J Clin Oncol. 2013 Sep 10;31(26):3173-5 - PubMed
  8. Science. 1990 Mar 2;247(4946):1079-82 - PubMed
  9. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5398-405 - PubMed
  10. Anticancer Res. 2010 Sep;30(9):3243-7 - PubMed
  11. Leuk Res. 2001 Jul;25(7):603-25 - PubMed
  12. Curr Opin Oncol. 2007 Jul;19(4):367-70 - PubMed
  13. N Engl J Med. 2006 Dec 7;355(23):2408-17 - PubMed
  14. J Clin Endocrinol Metab. 2003 Apr;88(4):1889-96 - PubMed
  15. Clin Cancer Res. 2004 Feb 1;10(3):897-908 - PubMed
  16. Ann Oncol. 2012 Jul;23(7):1680-7 - PubMed
  17. Ann Oncol. 2011 Feb;22(2):452-7 - PubMed
  18. Eur J Cancer. 2006 May;42(8):1093-103 - PubMed
  19. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):784-8 - PubMed
  20. JAMA. 2012 Mar 28;307(12):1265-72 - PubMed
  21. Nature. 1973 Jun 1;243(5405):290-3 - PubMed
  22. Int J Hematol. 2008 Dec;88(5):483-488 - PubMed
  23. Anticancer Drugs. 2005 Apr;16(4):461-6 - PubMed
  24. J Clin Pharmacol. 2004 Feb;44(2):158-62 - PubMed
  25. Blood. 2005 Mar 15;105(6):2473-9 - PubMed
  26. J Clin Oncol. 2003 Jun 1;21(11):2138-46 - PubMed
  27. Clin Cancer Res. 2008 May 1;14(9):2717-25 - PubMed
  28. Arch Dermatol. 2009 Jul;145(7):792-6 - PubMed
  29. J Clin Oncol. 2006 Sep 10;24(26):4340-6 - PubMed
  30. Blood. 2006 Sep 1;108(5):1469-77 - PubMed
  31. Biol Blood Marrow Transplant. 2011 Jan;17(1):1-17 - PubMed
  32. Blood. 2002 Mar 15;99(6):1928-37 - PubMed
  33. Clin Cancer Res. 2010 Jun 15;16(12):3288-95 - PubMed
  34. J Clin Oncol. 2006 Oct 10;24(29):4764-74 - PubMed
  35. Blood. 2009 Mar 5;113(10):2154-60 - PubMed
  36. Eur J Cancer. 2005 Aug;41(12):1751-7 - PubMed
  37. Clin Cancer Res. 2007 Apr 15;13(8):2369-77 - PubMed
  38. Expert Rev Anticancer Ther. 2008 Jan;8(1):99-110 - PubMed
  39. Blood. 2013 Dec 12;122(25):4111-8 - PubMed
  40. Clin Pharmacokinet. 2005;44(9):879-94 - PubMed
  41. J Clin Oncol. 2005 Feb 1;23(4):866-73 - PubMed
  42. J Clin Oncol. 2008 Feb 1;26(4):620-5 - PubMed
  43. Nat Med. 2001 Feb;7(2):228-34 - PubMed
  44. Br J Haematol. 2006 Jun;133(5):468-92 - PubMed
  45. Int J Cancer. 2007 Jul 15;121(2):257-64 - PubMed
  46. Methods Mol Med. 2006;125:93-106 - PubMed
  47. Leuk Res. 2009 Nov;33(11):1481-4 - PubMed
  48. J Clin Oncol. 2007 May 1;25(13):1785-91 - PubMed
  49. J Clin Oncol. 2012 Mar 20;30(9):914-20 - PubMed
  50. J Clin Oncol. 2005 Aug 20;23(24):5795-804 - PubMed
  51. Int J Cancer. 2001 May 1;92(3):354-60 - PubMed
  52. Lancet. 2003 Aug 16;362(9383):535-6 - PubMed
  53. Br J Dermatol. 2004 Jul;151(1):235-7 - PubMed
  54. Hematology Am Soc Hematol Educ Program. 2007;:435-43 - PubMed
  55. Blood. 2007 Jun 1;109(11):4635-40 - PubMed
  56. Leuk Res. 2006 Aug;30(8):965-70 - PubMed
  57. Best Pract Res Clin Haematol. 2006;19(3):595-615 - PubMed
  58. N Engl J Med. 2001 Apr 5;344(14):1038-42 - PubMed
  59. Pediatr Blood Cancer. 2005 May;44(5):511-5 - PubMed
  60. Proteomics. 2006 Feb;6(4):1151-7 - PubMed
  61. Nat Clin Pract Oncol. 2006 Nov;3(11):604-11 - PubMed
  62. N Engl J Med. 2003 Mar 13;348(11):994-1004 - PubMed
  63. Lancet. 2009 Mar 28;373(9669):1097-104 - PubMed
  64. Mayo Clin Proc. 2010 Feb;85(2):158-64 - PubMed
  65. Blood. 2002 May 15;99(10):3530-9 - PubMed
  66. CA Cancer J Clin. 1992 Mar-Apr;42(2):116-25 - PubMed
  67. Semin Hematol. 2003 Apr;40(2 Suppl 2):21-5 - PubMed
  68. N Engl J Med. 2010 Jun 17;362(24):2251-9 - PubMed
  69. Pharmacol Rev. 2003 Sep;55(3):401-23 - PubMed
  70. J Clin Oncol. 2008 Feb 1;26(4):626-32 - PubMed
  71. Nat Med. 1996 May;2(5):561-6 - PubMed
  72. Cancer. 2007 Jul 15;110(2):309-17 - PubMed
  73. Thyroid. 2010 Sep;20(9):975-80 - PubMed
  74. Am J Surg Pathol. 2004 Jul;28(7):889-94 - PubMed
  75. N Engl J Med. 2010 Jun 17;362(24):2260-70 - PubMed
  76. Int J Oncol. 2005 Sep;27(3):779-85 - PubMed
  77. Leukemia. 2006 Oct;20(10):1767-73 - PubMed
  78. ScientificWorldJournal. 2011;11:1908-31 - PubMed
  79. J Clin Oncol. 2014 Feb 10;32(5):402-8 - PubMed
  80. JAMA. 2011 Jun 8;305(22):2327-34 - PubMed
  81. Hematol Oncol Clin North Am. 1996 Oct;10(5):1023-9 - PubMed
  82. Cancer. 2002 Dec 1;95(11):2373-9 - PubMed
  83. Drugs. 2012 Oct 22;72(15):1953-63 - PubMed
  84. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed
  85. J Clin Oncol. 2013 Sep 10;31(26):3182-90 - PubMed
  86. Cancer. 1967 Nov;20(11):1841-50 - PubMed
  87. N Engl J Med. 2002 Aug 15;347(7):472-80 - PubMed
  88. Clin Cancer Res. 2010 Oct 1;16(19):4884-91 - PubMed
  89. Clin Cancer Res. 2009 Sep 15;15(18):5902-9 - PubMed
  90. J Clin Oncol. 2007 Mar 20;25(9):1107-13 - PubMed
  91. Blood. 2014 Feb 6;123(6):843-50 - PubMed
  92. Clin Cancer Res. 2011 Feb 1;17(3):406-15 - PubMed
  93. Blood. 2004 Oct 1;104(7):1931-9 - PubMed

Publication Types